Cytochrome P450 2A isoenzymes in freshly prepared blood lymphocytes isolated from rats and validation as a biomarker for clinical studies in humans

References

• Béréziat JC, Raffalli F, Schmezer P, Frei E, Geneste O, Lang MA. (1995). Cytochrome P450 2A of nasal epithelium: regulation and role in carcinogen metabolism. Mol Carcinog 14:130–139.
   PubMed Web of Science ®Google Scholar
• Baldwin SJ, Bramhall JL, Ashby CA, Yue L, Murdock PR, Hood SR, Ayrton AD, Clarke SE. (2006). Cytochrome P450 gene induction in rats ex vivo assessed by quantitative real-time reverse transcriptase-polymerase chain reaction (TaqMan). Drug Metab Dispos 34:1063–1069.
   PubMed Web of Science ®Google Scholar
• Camus AM, Geneste O, Honkakoski P, Béréziat JC, Henderson CJ, Wolf CR, Bartsch H, Lang MA. (1993). High variability of nitrosamine metabolism among individuals: role of cytochromes P450 2A6 and 2E1 in the dealkylation of N-nitrosodimethylamine and N-nitrosodiethylamine in mice and humans. Mol Carcinog 7:268–275.
   PubMed Web of Science ®Google Scholar
• Dey A, Parmar D, Dayal M, Dhawan A, Seth PK. (2001). Cytochrome P450 1A1 (CYP1A1) in blood lymphocytes evidence for catalytic activity and mRNA expression. Life Sci 69:383–393.
   PubMed Web of Science ®Google Scholar
• Dey A, Parmar D, Dhawan A, Dash D, Seth PK. (2002). Cytochrome P450 2E1 dependent catalytic activity and lipid peroxidation in rat blood lymphocytes. Life Sci 71:2509–2519.
   PubMed Web of Science ®Google Scholar
• Dey A, Yadav S, Dhawan A, Seth PK, Parmar D. (2006). Evidence for cytochrome P450 3A expression and catalytic activity in rat blood lymphocytes. Life Sci 79:1729–1735.
   PubMed Web of Science ®Google Scholar
• Di YM, Chow VD, Yang LP, Zhou SF. (2009). Structure, function, regulation and polymorphism of human cytochrome P450 2A6. Curr Drug Metab 10:754–780.
   PubMed Web of Science ®Google Scholar
• Fernandez-Salguero P, Gonzalez FJ. (1995). The CYP2A gene subfamily: species differences, regulation, catalytic activities and role in chemical carcinogenesis. Pharmacogenetics 5 Spec No:S123–S128.
   Google Scholar
• Furukawa M, Nishimura M, Ogino D, Chiba R, Ikai I, Ueda N, Naito S, Kuribayashi S, Moustafa MA, Uchida T, Sawada H, Kamataki T, Funae Y, Fukumoto M. (2004). Cytochrome p450 gene expression levels in peripheral blood mononuclear cells in comparison with the liver. Cancer Sci 95:520–529.
   PubMed Web of Science ®Google Scholar
• Gamieldien K, Maritz GS. (2004). Postnatal expression of cytochrome P450 1A1, 2A3, and 2B1 mRNA in neonatal rat lung: influence of maternal nicotine exposure. Exp Lung Res 30:121–133.
   PubMed Web of Science ®Google Scholar
• Gonzalez FJ. (1992). Human cytochromes P450: problems and prospects. Trends Pharmacol Sci 13:346–352.
   PubMed Web of Science ®Google Scholar
• Gu J, Walker VE, Lipinskas TW, Walker DM, Ding X. (1997). Intraperitoneal administration of coumarin causes tissue-selective depletion of cytochromes P450 and cytotoxicity in the olfactory mucosa. Toxicol Appl Pharmacol 146:134–143.
   PubMedGoogle Scholar
• Hannon-Fletcher MP, Barnett YA. (2008). Lymphocyte cytochrome P450 expression: inducibility studies in male Wistar rats. Br J Biomed Sci 65:1–6.
   PubMed Web of Science ®Google Scholar
• Higashi E, Fukami T, Itoh M, Kyo S, Inoue M, Yokoi T, Nakajima M. (2007). Human CYP2A6 is induced by estrogen via estrogen receptor. Drug Metab Dispos 35:1935–1941.
   PubMed Web of Science ®Google Scholar
• Honkakoski P, Negishi M. (1997). The structure, function, and regulation of cytochrome P450 2A enzymes. Drug Metab Rev 29:977–996.
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. (2007). Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116:496–526.
   PubMed Web of Science ®Google Scholar
• Khan AJ, Sharma A, Choudhuri G, Parmar D. (2011). Induction of blood lymphocyte cytochrome P450 2E1 in early stage alcoholic liver cirrhosis. Alcohol 45:81–87.
   PubMed Web of Science ®Google Scholar
• Kimura S, Kozak CA, Gonzalez FJ. (1989). Identification of a novel P450 expressed in rat lung: cDNA cloning and sequence, chromosome mapping, and induction by 3-methylcholanthrene. Biochemistry 28:3798–3803.
   PubMed Web of Science ®Google Scholar
• Kubota T, Nakajima-Taniguchi C, Fukuda T, Funamoto M, Maeda M, Tange E, Ueki R, Kawashima K, Hara H, Fujio Y, Azuma J. (2006). CYP2A6 polymorphisms are associated with nicotine dependence and influence withdrawal symptoms in smoking cessation. Pharmacogenomics J 6:115–119.
   PubMed Web of Science ®Google Scholar
• Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. (1951). Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275.
   PubMed Web of Science ®Google Scholar
• Malaiyandi V, Sellers EM, Tyndale RF. (2005). Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence. Clin Pharmacol Ther 77:145–158.
   PubMed Web of Science ®Google Scholar
• Matsuda Y, Yamakawa K, Saoo K, Hosokawa K, Yokohira M, Kuno T, Iwai J, Shirai T, Obika K, Kamataki T, Imaida K. (2007). CYP2A6 overexpression in human lung cancers correlates with a high malignant status. Oncol Rep 18:53–57.
   Google Scholar
• Messina ES, Tyndale RF, Sellers EM. (1997). A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J Pharmacol Exp Ther 282:1608–1614.
   PubMed Web of Science ®Google Scholar
• Nakajima M, Yoshida R, Fukami T, McLeod HL, Yokoi T. (2004). Novel human CYP2A6 alleles confound gene deletion analysis. FEBS Lett 569:75–81.
   PubMed Web of Science ®Google Scholar
• Nguyen LT, Ramanathan M, Weinstock-Guttman B, Dole K, Miller C, Planter M, Patrick K, Brownscheidle C, Jacobs LD. (2000). Detection of cytochrome P450 and other drug-metabolizing enzyme mRNAs in peripheral blood mononuclear cells using DNA arrays. Drug Metab Dispos 28:987–993.
   PubMed Web of Science ®Google Scholar
• Omiecinski CJ, Redlich CA, Costa P. (1990). Induction and developmental expression of cytochrome P450IA1 messenger RNA in rat and human tissues: detection by the polymerase chain reaction. Cancer Res 50:4315–4321.
   PubMed Web of Science ®Google Scholar
• Oscarson M. (2001). Genetic polymorphisms in the cytochrome P450 2A6 (CYP2A6) gene: implications for interindividual differences in nicotine metabolism. Drug Metab Dispos 29:91–95.
   PubMed Web of Science ®Google Scholar
• Oyama T, Sugio K, Uramoto H, Kawamoto T, Kagawa N, Nadaf S, Carbone D, Yasumoto K. (2007). Cytochrome P450 expression (CYP) in non-small cell lung cancer. Front Biosci 12:2299–2308.
   PubMed Web of Science ®Google Scholar
• Parmar D, Dhawan A, Seth PK. (1998). Evidence for O-dealkylation of 7-pentoxyresorufin by cytochrome P450 2B1/2B2 isoenzymes in brain. Mol Cell Biochem 189:201–205.
   Google Scholar
• Pitarque M, von Richter O, Oke B, Berkkan H, Oscarson M, Ingelman-Sundberg M. (2001). Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity. Biochem Biophys Res Commun 284:455–460.
   PubMed Web of Science ®Google Scholar
• Robottom-Ferreira AB, Aquino SR, Queiroga R, Albano RM, Ribeiro Pinto LF. (2003). Expression of CYP2A3 mRNA and its regulation by 3-methylcholanthrene, pyrazole, and beta-ionone in rat tissues. Braz J Med Biol Res 36:839–844.
   PubMed Web of Science ®Google Scholar
• Rossini A, de Almeida Simão T, Albano RM, Pinto LF. (2008). CYP2A6 polymorphisms and risk for tobacco-related cancers. Pharmacogenomics 9:1737–1752.
   PubMed Web of Science ®Google Scholar
• Ruwali M, Pant MC, Shah PP, Mishra BN, Parmar D. (2009). Polymorphism in cytochrome P450 2A6 and glutathione S-transferase P1 modifies head and neck cancer risk and treatment outcome. Mutat Res 669:36–41.
   PubMed Web of Science ®Google Scholar
• Shah PP, Saurabh K, Pant MC, Mathur N, Parmar D. (2009). Evidence for increased cytochrome P450 1A1 expression in blood lymphocytes of lung cancer patients. Mutat Res 670:74–78.
   PubMed Web of Science ®Google Scholar
• Sharma A, Saurabh K, Yadav S, Jain SK, Parmar D. (2012). Ethanol induced induction of cytochrome P450 2E1 and activation of mitogen activated protein kinases in peripheral blood lymphocytes. Xenobiotica 42:317–326.
   PubMed Web of Science ®Google Scholar
• Siest G, Jeannesson E, Marteau JB, Samara A, Marie B, Pfister M, Visvikis-Siest S. (2008). Transcription factor and drug-metabolizing enzyme gene expression in lymphocytes from healthy human subjects. Drug Metab Dispos 36:182–189.
   PubMed Web of Science ®Google Scholar
• Su T, Bao Z, Zhang QY, Smith TJ, Hong JY, Ding X. (2000). Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res 60:5074–5079.
   PubMed Web of Science ®Google Scholar
• Su T, Sheng JJ, Lipinskas TW, Ding X. (1996). Expression of CYP2A genes in rodent and human nasal mucosa. Drug Metab Dispos 24:884–890.
   PubMed Web of Science ®Google Scholar
• Su T, Zhang QY, Zhang J, Swiatek P, Ding X. (2002). Expression of the rat CYP2A3 gene in transgenic mice. Drug Metab Dispos 30:548–552.
   Google Scholar
• Tyndale RF, Sellers EM. (2001). Variable CYP2A6-mediated nicotine metabolism alters smoking behavior and risk. Drug Metab Dispos 29:548–552.
   PubMed Web of Science ®Google Scholar
• Wang J, Pitarque M, Ingelman-Sundberg M. (2006). 3’-UTR polymorphism in the human CYP2A6 gene affects mRNA stability and enzyme expression. Biochem Biophys Res Commun 340:491–497.
   PubMedGoogle Scholar
• Waxman DJ, Chang TK. (1998). Spectrofluorometric analysis of CYP2A6-catalyzed coumarin 7-hydroxylation. Methods Mol Biol 107:111–116.
   Google Scholar